KYOWA KIRIN CO. LTD./ JP3256000005 /
| 6/11/2024 10:05:05 AM | Chg. -0.100 | Volume | Bid11:50:24 AM | Ask11:50:24 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 16.100EUR | -0.62% | 0 Turnover: 0.000 |
15.700Bid Size: 1,050 | 16.500Ask Size: 1,000 | 8.65 bill.EUR | - | - |
GlobeNewswire
5/23
Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first pote...
GlobeNewswire
5/21
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapano...
GlobeNewswire
5/16
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
GlobeNewswire
5/8
Pharming Group reports first quarter 2024 financial results and provides business update
GlobeNewswire
5/7
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Ir...
GlobeNewswire
5/3
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024...
GlobeNewswire
5/1
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Ch...
GlobeNewswire
4/23
AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval...
GlobeNewswire
4/10
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as Pr...
GlobeNewswire
3/25
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...
GlobeNewswire
3/20
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Ap...
